Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry

mAbs

Volumn 6, Issue 6, 2014, Pages 1464-1473

  Gahoual, Rabah ^a   Biacchi, Michäel ^a   Chicher, Johana ^a   Kuhn, Lauriane ^a   Hammann, Philippe ^a   Beck, Alain ^b   Leize Wagner, Emmanuelle ^a   François, Yannis N ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Biobetter; Biosimilar; Cetuximab; Complete sequence coverage; Glycoforms semiquantitative analysis; Glycosylations; Mass spectrometry; Monoclonal antibodies; Peptide mapping; Posttranslational modifications; Sheathless capillary electrophoresis; Transient isotachophoresis; Trastuzumab

Indexed keywords

AMINO ACID; BIOSIMILAR AGENT; CETUXIMAB; GLYCOPROTEIN; MONOCLONAL ANTIBODY; TRASTUZUMAB; POLYSACCHARIDE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; CAPILLARY ZONE ELECTROPHORESIS; CONTROLLED STUDY; ISOTACHOPHORESIS; MASS SPECTROMETRY; METHODOLOGY; PROTEIN PROCESSING; TANDEM MASS SPECTROMETRY; CAPILLARY ELECTROPHORESIS; GLYCOSYLATION; MOLECULAR GENETICS; PROCEDURES; REPRODUCIBILITY; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOSIMILAR PHARMACEUTICALS; ELECTROPHORESIS, CAPILLARY; GLYCOSYLATION; ISOTACHOPHORESIS; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, PROTEIN; TANDEM MASS SPECTROMETRY;

EID: 84920847485     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.36305     Document Type: Article

References (47)

1. Beck A, Carter PJ, Gerber H-P, Lugovskoy AA, Wurch T, Junutula JR, Kontermann R, Mabry R, Ghayur T. 8th annual european antibody congress 2012: November 27-28, 2012, Geneva, Switzerland. mAbs 2013; 5:339-57; PMID:23493119; http://dx.doi.org/ 10.4161/mabs.24105
2. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi.org/ 10.1021/ac3032355
3. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
4. Reichert JM. Antibodies to watch in 2013: Mid-year update. mAbs 2013; 5:513-7; PMID:23727858; http://dx.doi.org/10.4161/mabs.24990
5. Kotsovilis S, Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol 2014; 1060:37-59; PMID:24037835; http:// dx.doi.org/10.1007/978-1-62703-586-6-3
6. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269-77; PMID:12612576; http://dx.doi.org/10.1038/nm0303-269
7. Agency EM. Guideline on similar biological medicinal products. 22 May 2013; CHMP43704 Rev 1.
8. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry. mAbs 2013; 5:621-3; PMID: 23924791; http://dx.doi.org/10.4161/mabs.25864
9. Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, Van Dorsselaer A, Sanglier-Cianferani S. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trac-Trends Anal Chem 2013; 48:81-95; PMID:23032066; http://dx. doi.org/10.1016/j.trac.2013.02.014
10. Fornelli L, Ayoub D, Aizikov K, Beck A, Tsybin YO. Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry. Anal Chem 2014; 86:3005-12; PMID:24588056; http://dx.doi.org/10.1021/ ac4036857
11. Rosati S, Thompson NJ, Barendregt A, Hendriks LJA, Bakker ABH, de Kruif J, Throsby M, van Duijn E, Heck AJR. Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry. Anal Chem 2012; 84:7227-32; PMID: 22882109; http://dx.doi.org/10.1021/ac301611d
12. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi.org/ 10.1021/ac3002885
13. Ambrogelly A, Liu Y-H, Li H, Mengisen S, Yao B, Xu W, Cannon-Carlson S. Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide. mAbs 2012; 4:701-9; PMID:22932441; http://dx.doi.org/ 10.4161/mabs.21614
14. European Medicines Agency (EMA). Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. 2009; EMEA/CHMP/BWP/157653/2007
15. Damen CN, Chen W, Chakraborty A, Oosterhout M, Mazzeo J, Gebler J, Schellens JM, Rosing H, Beijnen J. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 2009; 20:2021-33; PMID:19744865; http://dx.doi.org/10.1016/j.jasms. 2009.07.017
16. Rustandi RR, Wang Y. Use of CE-SDS gel for characterization of monoclonal antibody hinge region clipping due to copper and high pH stress. Electrophoresis 2011; 32:3078-84; PMID:22145164; http://dx.doi. org/10.1002/elps.201100186
17. Michels DA, Tu AW, McElroy W, Voehringer D, Salas-Solano O. Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection. Anal Chem 2012; 84:5380-6; PMID:22663182; http://dx.doi.org/10.1021/ac3008847
18. Wollacott RB, Casaz PL, Morin TJ, Zhu HL, Anderson RS, Babcock GJ, Que J, Thomas WD, Ozturk SS. Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography. Mabs 2013; 5:925-35; PMID:23995619; http://dx.doi.org/10.4161/mabs.26192
19. Heudi O, Barteau S, Zimmer D, Schmidt J, Bill K, Lehmann N, Bauer C, Kretz O. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MSMS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008; 80:4200-7; PMID: 18465883; http://dx.doi.org/10.1021/ac800205s
20. Beck A, Bussat MC, Zorn N, Robillard V, Klin-guer-Hamour C, Chenu S, Goetsch L, Corvaia N, Van Dorsselaer A, Haeuw JF. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells. J Chromatogr B-Anal Tech Biomed Life Sci 2005; 819:203-18; PMID:15833284; http://dx.doi.org/ 10.1016/j.jchromb.2004.06.052
21. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaïa N, Ionescu R, Beck A. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009; 392:145-54; PMID:19497295; http://dx. doi.org/10.1016/j.ab.2009.05.043
22. Fekete S, Beck A, Veuthey J-L, Guillarme D. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal 2014; 101:161-173; PMID:24816223; http://dx.doi. org/10.1016/j.jpba.2014.04.011
23. Gahoual R, Burr A, Busnel J-M, Kuhn L, Hammann P, Beck A, François Y-N, Leize-Wagner E. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. mAbs 2013; 5:479-90; PMID:23563524; http://dx.doi.org/10.4161/mabs.23995
24. Moini M. Simplifying CE-MS Operation. 2. Interfacing Low-Flow Separation Techniques to Mass Spectrometry Using a Porous Tip. Anal Chem 2007; 79:4241-6; PMID:17447730; http://dx.doi.org/ 10.1021/ac0704560
25. Haselberg R, Ratnayake CK, de Jong GJ, Somsen GW. Performance of a sheathless porous tip sprayer for capillary electrophoresis-electrospray ionization-mass spectrometry of intact proteins. J Chromatogr A 2010; 1217:7605-11; PMID:20970804; http://dx.doi.org/ 10.1016/j.chroma.2010.10.006
26. Busnel J-M, Schoenmaker B, Ramautar R, Carrasco-Pancorbo A, Ratnayake C, Feitelson JS, Chapman JD, Deelder AM, Mayboroda OA. High capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a porous sheathless interface with tran-sient-isotachophoresis. Anal Chem 2010; 82:9476-83; PMID:21028888; http://dx.doi.org/10.1021/ ac102159d
27. Sarg B, Faserl K, Kremser L, Halfinger B, Sebastiano R, Lindner HH. Comparing and combining capillary electrophoresis electrospray ionization mass spectrometry and nano-liquid chromatography electrospray ionization mass spectrometry for the characterization of posttranslationally modified histones. Mol Cell Proteomics 2013; 12:2640-56; PMID:23720761; http://dx.doi. org/10.1074/mcp.M112.024109
28. Ramautar R, Busnel JM, Deelder AM, Mayboroda OA. Enhancing the coverage of the urinary metabolome by sheathless capillary electrophoresis-mass spectrometry. Anal Chem 2012; 84:885-92; PMID:22148170; http://dx.doi.org/10.1021/ac202407v
29. Bonvin G, Veuthey JL, Rudaz S, Schappler J. Evaluation of a sheathless nanospray interface based on a porous tip sprayer for CE-ESI-MS coupling. Electrophoresis 2012; 33:552-62; PMID:22451047; http:// dx.doi.org/10.1002/elps.201100461
30. Gahoual R, Busnel J-M, Wolff P, Fraņcois Y, Leize-Wagner E. Novel sheathless CE-MS interface as an original and powerful infusion platform for nanoESI study: from intact proteins to high molecular mass noncovalent complexes. Anal Bioanal Chem 2014; 406:1029-38; PMID:23881366; http://dx.doi.org/ 10.1007/s00216-013-7226-1
31. Larsson M, Lutz ESM. Transient isotachophoresis for sensitivity enhancement in capillary electrophoresismass spectrometry for peptide analysis. Electrophoresis 2000; 21:2859-65; PMID:11001295; http://dx.doi. org/10.1002/1522-2683(20000801)21:14%3c2859:: AID-ELPS2859%3e3.0.CO;2-F
32. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi. org/10.1016/j.ccr.2005.03.003
33. Gunturu KSW, Woo Y, Beaubier N, Remotti HE, Saif WM. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol 2013; 5:143-51; PMID:23450234; http://dx.doi.org/ 10.1177/1758834012469429
34. Dubois M, Fenaille F, Clement G, Lechmann M, Tabet J-C, Ezan E, Becher F. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008; 80:1737-45; PMID:18225864; http://dx. doi.org/10.1021/ac7021234
35. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343:1235681-1-1235681-8; PMID:24385630; http:// dx.doi.org/10.1126/science.1235681
36. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0
37. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30:356-62; PMID:19552968; http://dx.doi.org/10.1016/j.tips. 2009.04.007
38. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008; 8:2858-71; PMID:18655055; http://dx. doi.org/10.1002/pmic.200700968
39. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorptionionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18; PMID: 17362871; http://dx.doi.org/10.1016/j.ab.2007.01.023
40. Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for Galactose-a-1,3-Galactose. New Engl J Med 2008; 358:1109-17; PMID:18337601; http://dx.doi. org/10.1056/NEJMoa074943
41. Wagner-Rousset E, Bednarczyk A, Bussat M-C, Colas O, Corvaïa N, Schaeffer C, Van Dorsselaer A, Beck A. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B 2008; 872:23-37; PMID:18672411; http://dx.doi.org/ 10.1016/j.jchromb.2008.03.032
42. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B 2001; 752:233-45; PMID:11270864; http://dx.doi.org/ 10.1016/S0378-4347(00)00548-X
43. Diepold K, Bomans K, Wiedmann M, Zimmermann B, Petzold A, Schlothauer T, Mueller R, Moritz B, Stracke JO, Molhoj M, et al. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. Plos One 2012; 7:1-11; PMID:22272329; http://dx.doi.org/10.1371/journal. pone.0030295
44. Jefferis R, Lefranc M-P. Human immunoglobulin allotypes: Possible implications for immunogenicity. mAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/ 10.4161/mabs.1.4.9122
45. Beck A, Cochet O, Wurch T. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Disc 2010; 5:95-111; PMID:22823974; http://dx.doi.org/10.1517/ 17460440903413504
46. Beck A, Reichert JM. Marketing approval of mogamulizumab A triumph for glyco-engineering. Mabs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/ 10.4161/mabs.20996
47. Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. mAbs 2013; 5:699-710; PMID:23924801; http://dx.doi.org/ 10.4161/mabs.25423